Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of -11.21% and Operating profit at 7.90% over the last 5 years

With a fall in Net Sales of -28.99%, the company declared Very Negative results in Mar 25

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 16,344 Million (Large Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.13

Return on Equity

-16.57%

Price to Book

15.61

Revenue and Profits:

Net Sales:

61 Million

(Quarterly Results - Jun 2025)

Net Profit:

-25 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.92%

6 Months

-14.47%

1 Year

218.87%

2 Years

132.08%

3 Years

90.88%

4 Years

51.53%

5 Years

160.29%

Staidson (Beijing) Biopharmaceuticals Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-11.21%

EBIT Growth (5y)

7.90%

EBIT to Interest (avg)

-201.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

0.34

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

15.61

EV to EBIT

-229.99

EV to EBITDA

-318.45

EV to Capital Employed

17.87

EV to Sales

61.51

PEG Ratio

Dividend Yield

ROCE (Latest)

-7.77%

ROE (Latest)

-16.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -28.90% vs -16.59% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8,366.67% vs 100.29% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "61.50",
          "val2": "86.50",
          "chgp": "-28.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.50",
          "val2": "6.20",
          "chgp": "-430.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.80",
          "val2": "0.30",
          "chgp": "-8,366.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-434.90%",
          "val2": "-19.50%",
          "chgp": "-41.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.97% vs -33.62% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 62.97% vs -102.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "320.50",
          "val2": "360.00",
          "chgp": "-10.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.00",
          "val2": "-339.90",
          "chgp": "93.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "1.30",
          "chgp": "-46.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-147.70",
          "val2": "-398.90",
          "chgp": "62.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-136.80%",
          "val2": "-1,034.50%",
          "chgp": "89.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

61.50

86.50

-28.90%

Operating Profit (PBDIT) excl Other Income

-20.50

6.20

-430.65%

Interest

0.10

0.30

-66.67%

Exceptional Items

0.00

Consolidate Net Profit

-24.80

0.30

-8,366.67%

Operating Profit Margin (Excl OI)

-434.90%

-19.50%

-41.54%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -28.90% vs -16.59% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8,366.67% vs 100.29% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

320.50

360.00

-10.97%

Operating Profit (PBDIT) excl Other Income

-21.00

-339.90

93.82%

Interest

0.70

1.30

-46.15%

Exceptional Items

0.00

Consolidate Net Profit

-147.70

-398.90

62.97%

Operating Profit Margin (Excl OI)

-136.80%

-1,034.50%

89.77%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -10.97% vs -33.62% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 62.97% vs -102.49% in Dec 2023

All Annual Results

Company CV

About Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available